Chang John T, Lichtenstein Gary R
Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104-4283, USA.
Nat Clin Pract Gastroenterol Hepatol. 2006 Apr;3(4):220-8. doi: 10.1038/ncpgasthep0447.
In the past decade, advances in the understanding of the pathogenesis of inflammatory bowel disease have permitted the development of agents directed against rational therapeutic targets. In particular, various antagonists of tumor-necrosis factor-alpha have been developed. These include infliximab, adalimumab, certolizumab (CDP870), CDP571, etanercept, and onercept. Clinical trials of these agents have demonstrated varying degrees of clinical efficacy. The use of these agents can be limited by infection, immunogenicity, acute infusion reactions, delayed hypersensitivity reactions, and autoimmune phenomena. This review provides insights into the use of antagonists of tumor-necrosis factor-alpha for the treatment of inflammatory bowel disease.
在过去十年中，对炎症性肠病发病机制认识的进展使得针对合理治疗靶点的药物得以开发。特别是，已经开发出了多种肿瘤坏死因子-α拮抗剂。这些包括英夫利昔单抗、阿达木单抗、赛妥珠单抗（CDP870）、CDP571、依那西普和昂克妥。这些药物的临床试验已证明了不同程度的临床疗效。这些药物的使用可能会受到感染、免疫原性、急性输注反应、迟发型超敏反应和自身免疫现象的限制。本综述提供了关于肿瘤坏死因子-α拮抗剂用于治疗炎症性肠病的见解。
